<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Verdiesen RMG</submitter><funding>Dutch Research Council (NWO)</funding><pagination>269</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11266950</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Higher age-specific circulating anti-Müllerian hormone (AMH) levels have been linked to a lower risk of cardiometabolic outcomes. However, whether AMH has a casual role in the etiology of these diseases is unknown. The objective of this study was therefore to explore if circulating AMH levels have a causal effect on risk of coronary artery disease (CAD), ischemic stroke and type 2 diabetes (T2D) in women, using a two-sample Mendelian randomization (MR) approach.&lt;h4>Methods&lt;/h4>We used four single nucleotide polymorphisms (SNPs) from the most recent AMH GWAS meta-analysis as instrumental variables. Summary-level data for CAD (n = 149,752; 11,802 cases), ischemic stroke (n = 17,541; 4678 cases) and T2D (n = 464,389; 30,052 cases) were extracted from the UK Biobank, the Str</pubmed_abstract><journal>Reviews in cardiovascular medicine</journal><pubmed_title>Anti-Mullerian Hormone and Cardiometabolic Disease in Women: A Two-Sample Mendelian Randomization Study.</pubmed_title><pmcid>PMC11266950</pmcid><funding_grant_id>022.005.021</funding_grant_id><pubmed_authors>van der Harst P</pubmed_authors><pubmed_authors>Mahajan A</pubmed_authors><pubmed_authors>Verdiesen RMG</pubmed_authors><pubmed_authors>van Gils CH</pubmed_authors><pubmed_authors>Onland-Moret NC</pubmed_authors><pubmed_authors>Said MA</pubmed_authors><pubmed_authors>van der Schouw YT</pubmed_authors><pubmed_authors>von Berg J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-Mullerian Hormone and Cardiometabolic Disease in Women: A Two-Sample Mendelian Randomization Study.</name><description>&lt;h4>Background&lt;/h4>Higher age-specific circulating anti-Müllerian hormone (AMH) levels have been linked to a lower risk of cardiometabolic outcomes. However, whether AMH has a casual role in the etiology of these diseases is unknown. The objective of this study was therefore to explore if circulating AMH levels have a causal effect on risk of coronary artery disease (CAD), ischemic stroke and type 2 diabetes (T2D) in women, using a two-sample Mendelian randomization (MR) approach.&lt;h4>Methods&lt;/h4>We used four single nucleotide polymorphisms (SNPs) from the most recent AMH GWAS meta-analysis as instrumental variables. Summary-level data for CAD (n = 149,752; 11,802 cases), ischemic stroke (n = 17,541; 4678 cases) and T2D (n = 464,389; 30,052 cases) were extracted from the UK Biobank, the Str</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2026-05-28T03:10:02.023Z</modification><creation>2025-08-28T03:09:09.984Z</creation></dates><accession>S-EPMC11266950</accession><cross_references><pubmed>39076620</pubmed><doi>10.31083/j.rcm2308269</doi></cross_references></HashMap>